Maintained Symptom Control Following a Shortage-Driven Switch to Immediate-Release Dextroamphetamine: A Case Report

ADHD is a neurodevelopmental condition marked by persistent symptoms of inattention, hyperactivity, and impulsivity. The gold standard pharmacotherapy for the treatment of ADHD is CNS psychostimulants. However, a shortage of CNS psychostimulants used for the treatment of ADHD has persisted since 2022, and many patients have been forced to switch medications or have been unable to obtain medication at all, raising concerns about symptom management and quality of life. This case report describes a…

via https://pubmed.ncbi.nlm.nih.gov/42306030/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20260627010904&v=2.20.0